# A Registry of Patients With Moderate to Severe Plaque Psoriasis

> **NCT02786186** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2376 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Secikinumab

## Key facts

- **NCT ID:** NCT02786186
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-23
- **Primary completion:** 2026-01-22
- **Final completion:** 2026-01-22
- **Target enrollment:** 2376 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02786186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02786186, "A Registry of Patients With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02786186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*